Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics

Executive Summary

Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.

You may also be interested in...



How Cipla Is Aligning Manufacturing Amid The Pandemic

Cipla senior management executive tells Scrip how the company is calibrating manufacturing as part of a wider business “reimagination” and accelerated digital adoption across its operations.

Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.

India's SPARC Keeps Paclitaxel Ambition Burning For Now

A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM004967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel